Published sequences do not support transfer of oseltamivir resistance mutations from avian to human influenza A virus strains

BMC Infectious Diseases

Sigvard Olofsson¹  Magnus Lindh¹  Peter Norberg¹ 

[1] Department of Infectious Diseases and Virology, Sahlgrenska Academy, University of Göteborg, Guldhedsgatan 10 B, Gothenburg, S-413 46, Sweden

关键词: Resistance mutations;    Oseltamivir resistance;    Tamiflu;    Avian influenza;    Influenza A;   

Others  :  1173923
DOI  :  10.1186/s12879-015-0860-9

 received in 2014-08-12, accepted in 2015-02-26,  发布年份 2015

【 摘 要 】

Background

Tamiflu (oseltamivir phosphate ester, OE) is a widely used antiviral active against influenza A virus. Its active metabolite, oseltamivir carboxylate (OC), is chemically stable and secreted into wastewater treatment plants. OC contamination of natural habitats of waterfowl might induce OC resistance in influenza viruses persistently infecting waterfowl, and lead to transfer of OC-resistance from avian to human influenza. The aim of this study was to evaluate whether such has occurred.

Methods

A genomics approach including phylogenetic analysis and probability calculations for homologous recombination was applied on altogether 19,755 neuraminidase (N1 and N2) genes from virus sampled in humans and birds, with and without resistance mutations.

Results

No evidence for transfer of OE resistance mutations from avian to human N genes was obtained, and events suggesting recombination between human and avian influenza virus variants could not be traced in the sequence material studied.

Conclusions

The results indicate that resistance in influenza viruses infecting humans is due to the selection pressure posed by the global OE administration in humans rather than transfer from avian influenza A virus strains carrying mutations induced by environmental exposure to OC.

【 授权许可】

   
2015 Norberg et al.; licensee BioMed Central.

【 图 表 】

Figure 1.

Figure 2.

【 参考文献 】

• [1]Schunemann HJ, Hill SR, Kakad M, Bellamy R, Uyeki TM, Hayden FG, et al.: WHO rapid advice guidelines for pharmacological management of sporadic human infection with avian influenza a (H5N1) virus. Lancet Infect Dis 2007, 7(1):21-31.
• [2]He G, Massarella J, Ward P: Clinical pharmacokinetics of the prodrug oseltamivir and its active metabolite Ro 64-0802. Clin Pharmacokinet 1999, 37(6):471-84.
• [3]Slater FR, Singer AC, Turner S, Barr JJ, Bond PL: Pandemic pharmaceutical dosing effects on wastewater treatment: no adaptation of activated sludge bacteria to degrade the antiviral drug oseltamivir (Tamiflu(R)) and loss of nutrient removal performance. FEMS Microbiol Lett 2011, 315(1):17-22.
• [4]Soderstrom H, Jarhult JD, Olsen B, Lindberg RH, Tanaka H, Fick J: Detection of the antiviral drug oseltamivir in aquatic environments. Plos One 2009, 4(6):e6064.
• [5]Ghosh GC, Nakada N, Yamashita N, Tanaka H: Oseltamivir carboxylate, the active metabolite of oseltamivir phosphate (Tamiflu), detected in sewage discharge and river water in Japan. Environ Health Perspect 2010, 118(1):103-7.
• [6]Orozovic G, Orozovic K, Lennerstrand J, Olsen B: Detection of resistance mutations to antivirals oseltamivir and zanamivir in avian influenza A viruses isolated from wild birds. Plos One 2011, 6(1):e16028.
• [7]Jarhult JD, Muradrasoli S, Wahlgren J, Soderstrom H, Orozovic G, Gunnarsson G, et al.: Environmental levels of the antiviral oseltamivir induce development of resistance mutation H274Y in influenza A/H1N1 virus in mallards. Plos One 2011, 6(9):e24742.
• [8]Singer AC, Nunn MA, Gould EA, Johnson AC: Potential risks associated with the proposed widespread use of Tamiflu. Environ Health Perspect 2007, 115(1):102-6.
• [9]Ferraris O, Lina B: Mutations of neuraminidase implicated in neuraminidase inhibitors resistance. J Clin Virol 2008, 41(1):13-9.
• [10]Olofsson S, Kumlin U, Dimmock K, Arnberg N: Avian influenza and sialic acid receptors: more than meets the eye. Lancet Infect Dis 2005, 5:184-8.
• [11]Lam TT, Wang J, Shen Y, Zhou B, Duan L, Cheung CL, et al.: The genesis and source of the H7N9 influenza viruses causing human infections in China. Nature 2013, 502(7470):241-4.
• [12]Taubenberger JK, Kash JC: Influenza virus evolution, host adaptation, and pandemic formation. Cell Host Microbe 2010, 7(6):440-51.
• [13]Felsenstein J: Phylip. Distributed by the Author. Department of Genome Sciences, University of Washington, Seattle; 2005.
• [14]Bruen TC, Philippe H, Bryant D: A simple and robust statistical test for detecting the presence of recombination. Genetics 2006, 172(4):2665-81.
• [15]Martin DP, Lemey P, Lott M, Moulton V, Posada D, Lefeuvre P: RDP3: a flexible and fast computer program for analyzing recombination. Bioinformatics 2010, 26(19):2462-3.
• [16]Hao W: Evidence of intra-segmental homologous recombination in influenza A virus. Gene 2011, 481(2):57-64.
• [17]Stoner TD, Krauss S, DuBois RM, Negovetich NJ, Stallknecht DE, Senne DA, et al.: Antiviral susceptibility of avian and swine influenza virus of the N1 neuraminidase subtype. J Virol 2010, 84(19):9800-9.
• [18]Hay AJ, Gregory V, Douglas AR, Lin YP: The evolution of human influenza viruses. Philos Trans R Soc Lond B Biol Sci 2001, 356(1416):1861-70.
• [19]Obenauer JC, Denson J, Mehta PK, Su X, Mukatira S, Finkelstein DB, et al.: Large-scale sequence analysis of avian influenza isolates. Science 2006, 311(5767):1576-80.
• [20]He CQ, Han GZ, Wang D, Liu W, Li GR, Liu XP, et al.: Homologous recombination evidence in human and swine influenza A viruses. Virology 2008, 380(1):12-20.
• [21]Boni MF, Zhou Y, Taubenberger JK, Holmes EC: Homologous recombination is very rare or absent in human influenza A virus. J Virol 2008, 82(10):4807-11.
• [22]Chare ER, Gould EA, Holmes EC: Phylogenetic analysis reveals a low rate of homologous recombination in negative-sense RNA viruses. J Gen Virol 2003, 84(Pt 10):2691-703.
• [23]Chen Y, Chen YF: Extensive homologous recombination in classical swine fever virus: a re-evaluation of homologous recombination events in the strain AF407339. Saudi J Biol Sci 2014, 21(4):311-6.
• [24]Han GZ, Boni MF, Li SS: No observed effect of homologous recombination on influenza C virus evolution. Virol J 2010, 7:227. BioMed Central Full Text
• [25]Liu X, Wu C, Chen AY: Codon usage bias and recombination events for neuraminidase and hemagglutinin genes in Chinese isolates of influenza A virus subtype H9N2. Arch Virol 2010, 155(5):685-93.
• [26]McNicholl IR, McNicholl JJ: Neuraminidase inhibitors: zanamivir and oseltamivir. Ann Pharmacother 2001, 35(1):57-70.
• [27]Ghosh GC, Nakada N, Yamashita N, Tanaka H: Occurrence and fate of oseltamivir carboxylate (Tamiflu) and amantadine in sewage treatment plants. Chemosphere 2010, 81(1):13-7.
• [28]Sacca ML, Accinelli C, Fick J, Lindberg R, Olsen B: Environmental fate of the antiviral drug Tamiflu in two aquatic ecosystems. Chemosphere 2009, 75(1):28-33.